Flow Cytometry
Defines medical coverage criteria and reimbursement limitations for flow cytometry (immunophenotyping and DNA/cell cycle analysis) including indications covered, not-covered uses, applicable CPT/HCPCS codes, and billing/unit limits. Applies to members of Medical Mutual - Ohio per benefit coverage and government regulations.
03/05/2025 Reviewed and Updated: background, guidelines and recommendations, and evidence-based scientific references were updated; literature review did not necessitate modifications to coverage criteria.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.